Managing hypertriglyceridemia: What can we learn from cardiovascular outcomes trials?

Area of Science:

• Cardiology
• Metabolic Diseases
• Pharmacology

Background:

• Cardiovascular (CV) disease remains a significant health concern.
• Statin therapy is a cornerstone of CV risk reduction but does not eliminate risk in all patients.
• Elevated triglycerides (TGs) are implicated in CV disease pathogenesis.

Purpose of the Study:

• To review the role of triglycerides in cardiovascular risk.
• To evaluate the efficacy of triglyceride-lowering agents in CV risk reduction.
• To highlight specific findings regarding eicosapentaenoic acid in statin-treated patients.

Main Methods:

• Literature review of outcomes studies on triglyceride-lowering agents.
• Analysis of evidence supporting the link between TGs and CV disease.
• Examination of clinical trial data, including specific studies on eicosapentaenoic acid.

Main Results:

• Cardiovascular risk persists in some patients despite statin treatment.
• Outcomes studies for general TG-lowering agents have yielded inconsistent results.
• Eicosapentaenoic acid demonstrated a significant reduction in coronary events in hypercholesterolemic patients on statins.

Conclusions:

• Triglycerides play a role in cardiovascular disease.
• The effectiveness of TG-lowering treatments for CV risk reduction requires further investigation.
• Eicosapentaenoic acid represents a promising therapeutic option for specific patient populations.